Is Romiplostim included in medical insurance and reimbursement policy?

Romiplostim (Romiplostim), as a recombinant human thrombopoietin receptor agonist (TPO-RA), has been officially launched in China for the treatment of patients with thrombocytopenia such as chronic immune thrombocytopenia (ITP). It stimulates the proliferation and differentiation of bone marrow megakaryocytes and increases platelet production, thereby effectively improving patients' platelet levels and reducing the risk of bleeding. With the popularization of clinical use, the issue of medical insurance coverage of Ropremilast has also become a focus of concern for patients and their families.

At present, Roprostim has been included in the domestic medical insurance catalog. Whether it is an imported drug or a domestic drug, patients can enjoy a certain percentage of reimbursement if they meet the medication conditions. The reference price of imported loplastin in the market is about more than 2,000 yuan per tube, while the price of domestically produced loplastin is relatively low, about more than 1,000 yuan per tube. The specific actual costs will vary depending on different regions, hospitals and medical insurance policies. Patients should consult the local hospital pharmacy to obtain accurate price and reimbursement ratio information before taking medication.

Medical insurance reimbursement policies usually require patients to provide a clear disease diagnosis and doctor's prescription, and may require declarations under specific departments or diseases of the hospital. Some regions may have a preliminary approval process for patients using Ropremilast for the first time to ensure the rational use of the drug and the effective management of medical insurance resources. When patients receive medical treatment, they should cooperate with the hospital to complete relevant procedures and keep medical receipts in order to smoothly enjoy medical insurance reimbursement benefits.

In general, the domestic launch of Roprostim and its inclusion in medical insurance have provided patients with financial support for the treatment of thrombocytopenia, while ensuring the accessibility and sustainability of clinical medication. In order to obtain the most accurate price and reimbursement information, it is recommended that patients consult the local hospital pharmacy or medical insurance department for specific policies before taking medication, and use medications rationally under the guidance of a doctor to ensure a balance between efficacy, safety and economic burden.

Reference materials:https://www.drugs.com/